Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

PURPOSE: Inhibition of ribonucleotide reductase reduces the availability of the endogenous pool of deoxycytidine and may increase cytarabine (AraC) cytotoxicity. We performed a phase I dose escalation trial of AraC combined with GTI-2040, a 20-mer antisense oligonucleotide shown in preclinical studi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Klisovic, Rebecca B., Blum, William, Wei, Xiaohui, Liu, Shujun, Liu, Zhongfa, Xie, Zhiliang, Vukosavljevic, Tamara, Kefauver, Cheryl, Huynh, LeNguyen, Pang, Jiuxia, Zwiebel, James A., Devine, Steven, Byrd, John C., Grever, Michael R., Chan, Kenneth, Marcucci, Guido
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2993318/
https://ncbi.nlm.nih.gov/pubmed/18559610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0109
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados